Avillion LLP

[On Demand]
Accelerating global drug development through successful partnering for patient benefit. Our objective is to enable our partners to continue to develop their most important drug candidates without increasing the burden on their P&L or cash reserves.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
United Kingdom
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
PT027 an investigational fixed dose combination of budesonide & albuterol for treatment of asthma
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Chief Executive Officer
Avillion LLP